Introduction
A prefilled autoinjector that delivers a biologic drug, an inhaler that pairs a drug formulation with a precision delivery device, a drug-eluting stent, a transdermal patch: these are combination products, items that combine a drug, a biologic, and/or a device component into a single regulated product. They do not fit neatly into any one regulatory pathway, and the specialists who shepherd them through development and approval have one of the more cross-disciplinary jobs in the field. This article looks at what a combination product regulatory affairs specialist actually does day to day, the agency structure they work within, and what it takes to build a career in this corner of regulatory affairs.
What Counts as a Combination Product
A combination product, in FDA's definition, is any product composed of two or more regulated components, drug and device, biologic and device, drug and biologic, or all three, that are physically, chemically, or otherwise combined or mixed, packaged together, or designed to be used together. Familiar examples include prefilled syringes and autoinjectors, metered-dose and dry-powder inhalers, drug-eluting stents, transdermal patches, and certain wound-care products that pair a device with a drug substance. The regulatory complexity comes from the fact that each component would normally be reviewed under a different framework, drugs under the FD&C Act's drug provisions, devices under its device provisions, biologics under the Public Health Service Act, and a combination product has to be handled as one coherent regulatory submission rather than two or three separate ones.
The Lead Center and the Primary Mode of Action
One of the first and most consequential questions for any combination product is which FDA center will lead its review. The agency determines this largely through the product's primary mode of action (PMOA), essentially which component is most responsible for the product's intended therapeutic effect. A drug-eluting stent, for example, is typically led by the device center because the mechanical function of the stent is central to its use, even though a drug coating is part of the product. A prefilled autoinjector delivering a biologic, by contrast, is typically led by the biologics or drug center, with the device component treated as a delivery mechanism supporting that primary action.
FDA's Office of Combination Products exists specifically to make and document these lead-center determinations and to coordinate between CDER, CDRH, and CBER when a product's review genuinely requires input from more than one center. A combination product specialist needs to understand not just which center leads a given product, but how to work within a review that may still draw secondary input from a center that is not formally in the lead, since that secondary center's concerns can still meaningfully shape the review.
What the Job Actually Looks Like Day to Day
The defining feature of this role is translation and coordination across functions that do not naturally speak the same regulatory language. A combination product specialist spends a meaningful share of their time in cross-functional meetings bringing together drug or biologic formulation scientists, device engineers, human factors specialists, and quality teams, each of whom may be more fluent in their own regulatory framework than in the combination product rules that govern how their work fits together.
Concretely, day-to-day work includes building and maintaining the regulatory strategy for how the product will be classified and which center will lead its review, preparing the specific sections of a submission that address the combination product aspects (including the rationale for the PMOA determination when it is not obvious), coordinating device-specific requirements like design verification and validation documentation alongside the drug or biologic development package, and managing the unique cGMP requirements that apply specifically to combination products under 21 CFR Part 4, which layers device quality system elements onto the applicable drug or biologic manufacturing requirements.
Human Factors and Usability Work
Because many combination products are self-administered by patients, often with little or no clinical supervision, human factors and usability engineering plays an outsized role compared to many single-component drug products. A combination product specialist typically works closely with human factors specialists to plan and interpret usability studies, which assess whether real users, including patients with no medical training, can use the device component correctly and safely. Findings from these studies often feed directly back into labeling, instructions for use, and sometimes device design itself, and the regulatory specialist has to make sure that connection between usability findings and the submission package is documented clearly enough to satisfy reviewers.
Labeling for Combination Products
Labeling a combination product is genuinely more complex than labeling a drug or a device alone. Instructions for use have to cover both the pharmacological information a drug label would normally include and clear, tested instructions for operating the device component correctly, often for a lay user rather than a clinician. Getting this labeling right, and demonstrating through human factors data that it actually works for its intended users, is one of the areas where combination product submissions most often draw agency questions, which makes labeling strategy a core, not peripheral, part of the specialist's job.
Lifecycle and Change Management
Once a combination product is on the market, change management becomes its own specialized challenge. A manufacturing change to the device component, a new autoinjector supplier, a redesigned needle shield, a software update to a connected delivery device, has to be evaluated against both the device-side change control requirements and the drug or biologic postmarket change framework, and determining which regulatory pathway a given change triggers is rarely a simple lookup. Specialists in this space build judgment over time about which changes are minor and can be handled through routine quality processes and which require a formal regulatory filing or even a new submission.
Skills That Matter in This Role
- Working knowledge of both drug/biologic regulatory pathways and the device quality system regulation, enough to translate between the two rather than defer entirely to specialists in each
- Familiarity with 21 CFR Part 4 and how combination product cGMP requirements layer onto standard drug or device manufacturing rules
- Experience with, or close collaboration on, human factors and usability engineering processes
- Comfort managing cross-functional projects where no single function has full authority over the regulatory outcome
- Judgment about primary mode of action determinations and how to build a defensible rationale when a product's classification is not obvious
How People Build a Career in This Niche
Few people start their regulatory affairs career as a dedicated combination product specialist. Most arrive here from either the drug/biologic side, often after working on an injectable or inhaled product and gradually taking on more of the device-related submission work, or from the device side, after working on a product that incorporated a drug-coated or drug-delivering component. Companies with significant combination product portfolios, particularly in diabetes care, respiratory disease, and self-injectable biologics, are where this specialization is most concentrated, and experience on even one successful combination product submission tends to open doors to more of the same work elsewhere, since the pool of regulatory professionals with genuine cross-functional combination product experience remains relatively small.
Which Submission Pathway Combination Products Actually Use
Despite the cross-functional complexity, a combination product is still ultimately filed through one of the established submission pathways, an NDA or BLA when the lead center is CDER or CBER, or a 510(k) or PMA when the lead center is CDRH, with the non-lead component's requirements addressed within that single submission rather than as a separate filing. A specialist working on a drug-led combination product, for example, still has to build a submission that satisfies device-specific expectations, such as design controls documentation and human factors data, inside what is formally a drug or biologic application. Understanding how to structure that content so it reads clearly to reviewers who may be more accustomed to one type of application than the other is a specific, learned skill, and one of the places where an inexperienced team can create real submission delays simply by presenting device information in a format reviewers do not expect.
There is also a formal mechanism, the Request for Designation (RFD), that a sponsor can use to get FDA's binding determination on lead center and classification before committing to a full development and submission strategy. Specialists with combination product experience often advise on whether and when to use an RFD versus relying on informal pre-submission interactions with the agency, since the right choice depends on how genuinely ambiguous the product's classification is.
Working With CDMOs, Device Suppliers, and External Partners
Very few companies manufacture every component of a combination product in-house. A biologic may be manufactured by the sponsor while the delivery device, an autoinjector platform or a prefilled syringe system, comes from a specialized device supplier or contract manufacturer. This adds another layer to the specialist's coordination role: making sure that supplier's device master file, change notification practices, and quality agreements line up with what the combination product application and its postmarket obligations require. A change the device supplier considers routine, a new molding supplier for a component, for instance, may still trigger a regulatory evaluation on the sponsor's side, and part of the specialist's job is maintaining a working relationship with that supplier's regulatory and quality contacts so those changes surface early rather than after the fact.
Conclusion
Combination products sit at a genuine seam in the regulatory system, and the specialists who work on them spend their careers translating between frameworks that were not originally designed to overlap. It is demanding, cross-functional work that rewards people comfortable holding both a drug or biologic regulatory strategy and a device quality system in their head at the same time, and as more therapies move toward self-administered, device-delivered formats, that particular combination of skills is likely to stay in steady demand.
